Method of preventing preeclampsia

Details Method of preventing preeclampsia Method of preventing preeclampsia

2009-07-13

2011-11-01

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S172000, C514S026000, C514S025000, C536S004100

Reexamination Certificate

active

08048868

ABSTRACT:
A method of preventing preeclampsia including administering to a patient during an early stage of pregnancy a prophylactically-effective amount of resibufogenin. The administration of resibufogenin is periodically repeated. The method serves to prevent hypertension, proteinuria, and intrauterine growth restriction.

REFERENCES:
patent: 2004/0171087 (2004-09-01), Rech-Weichselbraun et al.
patent: 2006/0134106 (2006-06-01), Adair
patent: 2007/0014722 (2007-01-01), Puschett
patent: 2007/0292968 (2007-12-01), Anslyn et al.
Libby et al, “Pre-eclampsia and the later development of type 2 diabetes in mothers and their children: an intergenerational study”, Diabetologia (2007) 50:523-530.
Conrad, “Animal models of pre-eclampsia: do they exist?”, Fetal Medicine Review 1990; 2: 67-68.
Roberts et al., “Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy”, Hypertension 2003; 41; 437-445, American Heart Association.
Pridjian et al., “Preeclampsia. Part 2: Experimental and Genetic Considerations”, Obstetrical and Gynecological Survey, vol. 57, No. 9, pp. 619-640.
Ianosi-Irimie et al, “A Rat Model of Preeclampsia”, Clinical and Experimental Hypertension, 8:605-617, 2005.
Puschett, “The role of excessive volume expansion in the pathogenesis of preeclampsia”, Medical Hypotheses (2006) 67, 1125-1132.
Vu et al., “Involvement of Marinobufagenin in a Rat Model of Human Preeclampsia”, Am J. Nephrol 2005;25:520-528.
Schoner, “Endogenous cardiac glycosides, a new class of steroid hormones”, Eur. J. Biochem. 269, 2440-2448 (2002), FEBS 2002.
Fedorova et al., “Endogenous Na,K Pump Ligands Are Differentially Regulated During Acute NaCI Loading of Dahl Rats”, Circulation. Dec. 12, 2000, pp. 3009-3014.
Uddin et al., “Marinobufagenin Inhibits Proliferation and Migration of Cytotrophoblast and CHO Cells”, Placenta 29 (2008) 266-273.
Lamarca et al., “Marinobufagenin Impairs First Trimester Cytotrophoblast Differentiation”, Placenta 27 (2006) 984-988.
Melamed et al., “Molecular and Kinetic Basis for the Mixed Agonist/Antagonist Activity of Estriol”, Molecular Endocrinology 11: 1868-1878, 1997.
Spitz, “Progesterone receptor antagonists”, Current Opinion in Investigational Drugs 2006 7 (10):882-890.
Dvela, “Diverse biological responses to different cardiotonic steroids”, Pathophysiology 14 (2007 159-166.
Schoner et al., “Endogenous and Exogenous Cardiac Glycosides and their Mechanisms of Action”, Am J Cardiovasc Drugs 2007 7 (3) pp. 173-187.
Feldmann et al., “Role of Endosomal Na+—K+-ATPase and cardiac steroids in the regulation of endocytosis”, Am J Physical Cell Physiol 293: C885-C896, 2007.

Affiliated with

Also associated with

Rating

Method of preventing preeclampsia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of preventing preeclampsia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preventing preeclampsia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4308309